BMS Reports Positive China Phase III Data of Hepatitis C Treatment

Bristol-Myers Squibb released results from a successful Phase III trial of its all-oral hepatitis C combination treatment in an Asian group of patients, who were predominantly Chinese. Among the China patients, 91% achieved a sustained virologic response at post-treatment week 24 (SVR24). The BMS test, which enrolled patients with genotype 1b HVC, did not include either interferon or ribavirin as part of the regimen. More details.... Stock Symbol: (NYSE: BMY) Share this with colleagues: // //